Mandate

Vinge advises Bravida in connection with the listing of its SEK Senior Secured Floating Rate Notes on NASDAQ OMX Stockholm

December 20, 2013

Vinge has assisted Bravida Holding AB (publ) in connection with the admission to trading of its SEK 1.3 billion aggregate principal amount senior secured floating rate notes on the regulated market of NASDAQ OMX Stockholm. The senior secured floating rate notes were issued on 11 June 2013 and are also listed on the MTF Global Exchange Market (GEM) of the Irish Stock Exchange. The dual listing on NASDAQ OMX Stockholm entails that the notes can now also be traded on a regulated market.

Bravida is Scandinavia’s premier integrated supplier of technical installation and service solutions, with nearly 8,000 employees. Bravida offers specialist expertise and integrated solutions in electrical installations, heating & plumbing and HVAC and operates at all stages of the installation – from advice and project planning to installation and service. Bravida has offices at 150 locations in Sweden, Norway and Denmark.

Vinge’s team consisted of Peter Bäärnhielm, Dain Nevonen and Oskar Belani. Christina Kokko is client responsible partner.

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024